Skip to main content
Premium Trial:

Request an Annual Quote

No Competing Here

Aled Edwards, the CEO of the Structural Genomics Consortium, tells the Globe and Mail that it makes no sense for pharmaceutical scientists at different organizations to be working on the same problems. "The semiconductor industry in the '80s started to collaborate with one another on the platform," Edwards says. "They said: Every one of us generating a unique platform on which to build our hardware is silly, right? So let's pool resources, agree on the platform and innovate from there." And that is what he is promoting for pharma. "Drug discovery is making the medicine that people buy," he adds. "The stuff before what I call 'proof of concept' — why in the world are we competing over that?"

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.